Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease

Neurobiology of Disease

Volumn 23, Issue 1, 2006, Pages 44-53

  Tarditi, Alessia ^a   Camurri, Alessandra ^a   Varani, Katia ^b   Borea, Pier Andrea ^b   Woodman, Ben ^c   Bates, Gillian ^c   Cattaneo, Elena ^a   Abbracchio, Maria P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENYLATE CYCLASE; CYCLIC AMP; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; HUNTINGTON CHOREA; HYPOTHESIS; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; BASAL GANGLIA; CYCLIC AMP; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; RECEPTORS, ADENOSINE A2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIAZINES; TRIAZOLES;

EID: 33745134073     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.01.014     Document Type: Article

References (54)

1. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev., Neurosci. 5 5 (2004) 373-384
2. Blum D., Galas M.C., Gall D., Cuvelier L., and Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10 3 (2002) 410-426
3. Blum D., Hourez R., Galas M.C., Popoli P., and Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2 6 (2003) 366-374 Review
4. 2A antagonists. J. Neurosci. 23 12 (2003) 5361-5369
5. Bona E., Aden U., Gilland E., Fredholm B.B., and Hagberg H. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology 36 9 (1997) 1327-1338
6. 2A receptor ligands. Biochem. Pharmacol. 49 (1995) 461-469
7. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 72 (1976) 248-254
8. 2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43 2 (2003) 190-194
9. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19 8 (1999) 3248-3257
10. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., and Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24 3 (2001) 182-188 (Review)
11. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 4 (2001) 525-539
12. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23 3 (2003) 961-969
13. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. London, Ser. B Biol. Sci. 354 1386 (1999) 981-989 (Review)
14. Chen J.F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M.A., Fink J.S., and Schwarzschild M.A. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19 21 (1999) 9192-9200
15. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli Jr. N., and Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 10 (2001) RC143
16. 2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 280 14 (2005) 14331-14340
17. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 2 (2005) 310-320
18. 2A, A2b, and A3 receptors in the human enteric nervous system. J. Comp. Neurol. 439 1 (2001) 46-64
19. 2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. NeuroReport 10 4 (1999) 687-691
20. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. NeuroReport 11 11 (2000) 2591-2595
21. 2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus. Br. J. Pharmacol. 122 7 (1997) 1279-1284
22. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 3 (1997) 537-548
23. Dragatsis I., Dietrich P., and Zeitlin S. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse. Neurosci. Lett. 282 1-2 (2000) 37-40
24. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269 5222 (1995) 407-410
25. Ferre S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13 12 (1993) 5402-5406
26. Gao Y., and Phillis J.W. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55 3 (1994) PL61-PL65
27. 2A receptors reduces transmitter outflow. Neurobiol. Dis. 17 1 (2004) 77-88
28. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., and MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12 5 (2003) 497-508
29. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 3 (2000) 505-519
30. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431 3 (2001) 331-346
31. Huang N.K., Lin Y.W., Huang C.L., Messing R.O., and Chern Y. Activation of protein kinase A and atypical protein kinase C by A(2A) adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. J. Biol. Chem. 276 17 (2001) 13838-13846
32. Jacobson K.A., Hoffmann C., Cattabeni F., and Abbracchio M.P. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 4 3 (1999) 197-211
33. Jarabek B.R., Yasuda R.P., and Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127 Pt. 3 (2004) 505-516
34. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., and Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24 8 (2003) 1113-1121
35. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 3 (1996) 493-506
36. Mitchell I.J., Cooper A.J., and Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59 6 (1999) 691-719 (Review)
37. Munson P.J., and Rodbard D. Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 107 (1980) 220-239
38. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., and Hayden M.R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81 5 (1995) 811-823
39. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 Pt. 5 (2003) 1127-1135
40. 2A receptors in ischemia. Ann. N. Y. Acad. Sci. 939 (2001) 74-84
41. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287 2 (1995) 215-217
42. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 5 (2002) 1967-1975
43. 2A receptor protects sympathetic neurons against nerve growth factor withdrawal. J. Neurosci. Res. 77 2 (2004) 258-269
44. Reggio R., Pezzola A., and Popoli P. The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831 1-2 (1999) 315-318
45. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., and Cattaneo E. Wild type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20 10 (2000) 3705-3713
46. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 6 (1993) 971-983
47. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 97 14 (2000) 8093-8097
48. 2A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 15 7 (2001) 1245-1247
49. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 14 (2003) 2148-2150
50. Wanker E.E., Rovira C., Scherzinger E., Hasenbank R., Walter S., Tait D., Colicelli J., and Lehrach H. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6 3 (1997) 487-495
51. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., and Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 15 (1998) 9158-9167
52. Wellington C.L., Leavitt B.R., and Hayden M.R. Huntington disease: new insights on the role of huntingtin cleavage. J. Neural Transm., Suppl. 58 (2000) 1-17 (Review)
53. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., and Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11 2 (1995) 155-163
54. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 5529 (2001) 493-498